메뉴 건너뛰기




Volumn 39, Issue 3, 2012, Pages 276-286

Whole cell vaccines - Past progress and future strategies

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BEVACIZUMAB; CANCER VACCINE; CD20 ANTIBODY; CD40 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; OX40 LIGAND; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; WHOLE CELL VACCINE;

EID: 84861164690     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.02.007     Document Type: Article
Times cited : (129)

References (69)
  • 2
    • 0032503016 scopus 로고    scopus 로고
    • Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine
    • M.C. Thomas, T.F. Greten, D.M. Pardoll, E.M. Jaffee Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine Hum Gene Ther 9 1998 835 843 (Pubitemid 28197370)
    • (1998) Human Gene Therapy , vol.9 , Issue.6 , pp. 835-843
    • Thomas, M.C.1    Greten, T.F.2    Pardoll, D.M.3    Jaffee, E.M.4
  • 6
    • 0032573225 scopus 로고    scopus 로고
    • Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
    • R. Soiffer, T. Lynch, M. Mihm Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma Proc Natl Acad Sci U S A 95 1998 13141 13146
    • (1998) Proc Natl Acad Sci U S A , vol.95 , pp. 13141-13146
    • Soiffer, R.1    Lynch, T.2    Mihm, M.3
  • 7
    • 0036813199 scopus 로고    scopus 로고
    • GM-CSF-based cancer vaccines
    • DOI 10.1034/j.1600-065X.2002.18813.x
    • G. Dranoff GM-CSF-based cancer vaccines Immunol Rev 188 2002 147 154 (Pubitemid 35398872)
    • (2002) Immunological Reviews , vol.188 , pp. 147-154
    • Dranoff, G.1
  • 8
    • 0035152718 scopus 로고    scopus 로고
    • Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase i trial of safety and immune activation
    • Jaffee E, Hruban R, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 200;19;145-56.
    • (2001) J Clin Oncol , vol.9 , pp. 45-56
    • Jaffee, E.1    Hruban, R.2    Biedrzycki, B.3
  • 9
    • 79151486551 scopus 로고    scopus 로고
    • A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation
    • E. Lutz, C.J. Yeo, K.D. Lillemoe A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy, and immune activation Ann Surg 253 2011 328 335
    • (2011) Ann Surg , vol.253 , pp. 328-335
    • Lutz, E.1    Yeo, C.J.2    Lillemoe, K.D.3
  • 11
    • 79955547695 scopus 로고    scopus 로고
    • CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity
    • H. Shirota, D.M. Klinman CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity Cancer Immunol Immunother 60 2011 659 669
    • (2011) Cancer Immunol Immunother , vol.60 , pp. 659-669
    • Shirota, H.1    Klinman, D.M.2
  • 12
    • 0037439696 scopus 로고    scopus 로고
    • CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma
    • A.D. Sandler, H. Chihara, G. Kobayashi CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma Cancer Res 63 2003 394 399 (Pubitemid 36152498)
    • (2003) Cancer Research , vol.63 , Issue.2 , pp. 394-399
    • Sandler, A.D.1    Chihara, H.2    Kobayashi, G.3    Zhu, X.4    Miller, M.A.5    Scott, D.L.6    Krieg, A.M.7
  • 13
    • 4644254242 scopus 로고    scopus 로고
    • Enhanced tumor-specific long-term immunity of hemaggluttinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides
    • K. Hiraoka, S. Yamamoto, S. Otsuru Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides J Immunol 173 2004 4297 4307 (Pubitemid 39280657)
    • (2004) Journal of Immunology , vol.173 , Issue.7 , pp. 4297-4307
    • Hiraoka, K.1    Yamamoto, S.2    Otsuru, S.3    Nakai, S.4    Tamai, K.5    Morishita, R.6    Ogihara, T.7    Kaneda, Y.8
  • 14
    • 70450227479 scopus 로고    scopus 로고
    • CpG oligodeoxynucleotides as TLR9 agonists: Therapeutic applications in cancer
    • Y.M. Murad, T.M. Clay CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer BioDrugs 23 2009 361 375
    • (2009) BioDrugs , vol.23 , pp. 361-375
    • Murad, Y.M.1    Clay, T.M.2
  • 16
    • 27644457376 scopus 로고    scopus 로고
    • TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
    • DOI 10.1016/j.ccr.2005.10.012, PII S1535610805003314
    • D.A. Thomas, J. Massagué TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance Cancer Cell 8 2005 369 380 (Pubitemid 41579832)
    • (2005) Cancer Cell , vol.8 , Issue.5 , pp. 369-380
    • Thomas, D.A.1    Massague, J.2
  • 18
    • 78751503892 scopus 로고    scopus 로고
    • Phase i trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine
    • J. Olivares, P. Kumar, Y. Yu Phase I trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine Clin Cancer Res 17 2011 183 192
    • (2011) Clin Cancer Res , vol.17 , pp. 183-192
    • Olivares, J.1    Kumar, P.2    Yu, Y.3
  • 20
    • 78449237498 scopus 로고    scopus 로고
    • Signaling through OX40 enhances antitumor immunity
    • S.M. Jensen, L.D. Maston, M.J. Gough Signaling through OX40 enhances antitumor immunity Semin Oncol 37 5 2010 Oct 524 532
    • (2010) Semin Oncol , vol.37 , Issue.5 , pp. 524-532
    • Jensen, S.M.1    Maston, L.D.2    Gough, M.J.3
  • 21
    • 66049113612 scopus 로고    scopus 로고
    • OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
    • D. Hirschhorn-Cymerman, G.A. Rizzuto, T. Merghoub OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis J Exp Med 206 2009 1103 1116
    • (2009) J Exp Med , vol.206 , pp. 1103-1116
    • Hirschhorn-Cymerman, D.1    Rizzuto, G.A.2    Merghoub, T.3
  • 24
    • 23944461007 scopus 로고    scopus 로고
    • Vaccination with dendritic cells pulsed with apoptotic tumors in combination with Anti-OX40 and Anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice
    • DOI 10.1002/ijc.21098
    • C. Cuadros, A.L. Dominguez, P.L. Lollini Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice Int J Cancer 116 2005 934 943 (Pubitemid 41209201)
    • (2005) International Journal of Cancer , vol.116 , Issue.6 , pp. 934-943
    • Cuadros, C.1    Dominguez, A.L.2    Lollini, P.-L.3    Croft, M.4    Mittler, R.S.5    Borgstrom, P.6    Lustgarten, J.7
  • 25
    • 78449262545 scopus 로고    scopus 로고
    • Biology and clinical applications of CD40 in cancer treatment
    • E. Fonsatti, M. Maio, M. Altomonte, P. Hersey Biology and clinical applications of CD40 in cancer treatment Semin Oncol 37 2010 517 523
    • (2010) Semin Oncol , vol.37 , pp. 517-523
    • Fonsatti, E.1    Maio, M.2    Altomonte, M.3    Hersey, P.4
  • 26
    • 77956462624 scopus 로고    scopus 로고
    • Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model
    • M.R. Sorensen, P.J. Holst, M.A. Steffensen, J.P. Christensen, A.R. Thomsen Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model Vaccine 28 2010 6757 6764
    • (2010) Vaccine , vol.28 , pp. 6757-6764
    • Sorensen, M.R.1    Holst, P.J.2    Steffensen, M.A.3    Christensen, J.P.4    Thomsen, A.R.5
  • 27
    • 78549256115 scopus 로고    scopus 로고
    • Immune modulation with weekly dosing of an agonist CD40 antibody in a phase i study of patients with advanced solid tumors
    • J. Rüter, S.J. Antonia, H.A. Burris, R.D. Huhn, R.H. Vonderheide Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors Cancer Biol Ther 10 2010 983 993
    • (2010) Cancer Biol Ther , vol.10 , pp. 983-993
    • Rüter, J.1    Antonia, S.J.2    Burris, H.A.3    Huhn, R.D.4    Vonderheide, R.H.5
  • 28
    • 33846602242 scopus 로고    scopus 로고
    • A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease
    • DOI 10.1245/s10434-006-9196-4
    • S. Dessureault, D. Noyes, D. Lee A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease Ann Surg Oncol 14 2007 869 884 (Pubitemid 46175338)
    • (2007) Annals of Surgical Oncology , vol.14 , Issue.2 , pp. 869-884
    • Dessureault, S.1    Noyes, D.2    Lee, D.3    Dunn, M.4    Janssen, W.5    Cantor, A.6    Sotomayor, E.7    Messina, J.8    Antonia, S.J.9
  • 29
    • 79953154967 scopus 로고    scopus 로고
    • CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans
    • G.L. Beatty, E.G. Chiorean, M.P. Fishman CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
    • (2011) Science , vol.331 , pp. 1612-1616
    • Beatty, G.L.1    Chiorean, E.G.2    Fishman, M.P.3
  • 34
    • 33745125681 scopus 로고    scopus 로고
    • Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity
    • DOI 10.1073/pnas.0603503103
    • M. Jinushi, F.S. Hodi, G. Dranoff Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity Proc Natl Acad Sci U S A 103 2006 9190 9195 (Pubitemid 43902554)
    • (2006) Proceedings of the National Academy of Sciences of the United States of America , vol.103 , Issue.24 , pp. 9190-9195
    • Jinushi, M.1    Hodi, F.S.2    Dranoff, G.3
  • 35
    • 78049427830 scopus 로고    scopus 로고
    • Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape
    • R.L. Ferris, E.M. Jaffee, S. Ferrone Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape J Clin Oncol 28 2010 4390 4399
    • (2010) J Clin Oncol , vol.28 , pp. 4390-4399
    • Ferris, R.L.1    Jaffee, E.M.2    Ferrone, S.3
  • 36
    • 31544446098 scopus 로고    scopus 로고
    • Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells
    • DOI 10.1158/0008-5472.CAN-05-2429
    • J.M. Roda, R. Parihar, C. Magro, G.J. Nuovo, S. Tridandapani, W.E. Carson 3rd Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells Cancer Res 66 2006 517 526 (Pubitemid 43166061)
    • (2006) Cancer Research , vol.66 , Issue.1 , pp. 517-526
    • Roda, J.M.1    Parihar, R.2    Magro, C.3    Nuovo, G.J.4    Tridandapani, S.5    Carson III, W.E.6
  • 37
    • 78650385895 scopus 로고    scopus 로고
    • Active immunotherapy induces antibody responses that target tumor angiogenesis
    • J. Schoenfeld, M. Jinushi, Y. Nakazaki Active immunotherapy induces antibody responses that target tumor angiogenesis Cancer Res 70 2010 10150 10160
    • (2010) Cancer Res , vol.70 , pp. 10150-10160
    • Schoenfeld, J.1    Jinushi, M.2    Nakazaki, Y.3
  • 40
    • 0032741283 scopus 로고    scopus 로고
    • Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
    • D.I. Gabrilovich, T. Ishida, S. Nadaf, J.E. Ohm, D.P. Carbone Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function Clin Cancer Res 5 1999 2963 2970 (Pubitemid 29493976)
    • (1999) Clinical Cancer Research , vol.5 , Issue.10 , pp. 2963-2970
    • Gabrilovich, D.I.1    Ishida, T.2    Nadaf, S.3    Ohm, J.E.4    Carbone, D.P.5
  • 41
    • 73349118752 scopus 로고    scopus 로고
    • Dendritic cell recovery post-lymphodepletion: A potential mechanism for anti-cancer adoptive T cell therapy and vaccination
    • M.L. Salem, D.J. Cole Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Cancer Immunol Immunother 59 2010 341 353
    • (2010) Cancer Immunol Immunother , vol.59 , pp. 341-353
    • Salem, M.L.1    Cole, D.J.2
  • 42
    • 0041975925 scopus 로고    scopus 로고
    • Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution
    • DOI 10.1002/eji.200324034
    • J. Ma, W.J. Urba, L. Si, Y. Wang, B.A. Fox, H.M. Hu Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution Eur J Immunol 33 2003 2123 2132 (Pubitemid 37010029)
    • (2003) European Journal of Immunology , vol.33 , Issue.8 , pp. 2123-2132
    • Ma, J.1    Urba, W.J.2    Si, L.3    Wang, Y.4    Fox, B.A.5    Hu, H.-M.6
  • 43
    • 79960299888 scopus 로고    scopus 로고
    • Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy
    • S.A. Rosenberg, J.C. Yang, R.M. Sherry Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy Clin Cancer Res 17 2011 4550 4557
    • (2011) Clin Cancer Res , vol.17 , pp. 4550-4557
    • Rosenberg, S.A.1    Yang, J.C.2    Sherry, R.M.3
  • 46
    • 57749190791 scopus 로고    scopus 로고
    • Whole tumor cell vaccine with irradiated S180 cells as adjuvant
    • J. Li, A.V. King, S.L. Stickel Whole tumor cell vaccine with irradiated S180 cells as adjuvant Vaccine 27 2009 558 564
    • (2009) Vaccine , vol.27 , pp. 558-564
    • Li, J.1    King, A.V.2    Stickel, S.L.3
  • 48
    • 77749252468 scopus 로고    scopus 로고
    • Enhancement of antitumor immunity by low-dose total body irradiation is associated with selectively decreasing the proportion and number of T regulatory cells
    • R. Liu, S. Xiong, L. Zhang, Y. Chu Enhancement of antitumor immunity by low-dose total body irradiation is associated with selectively decreasing the proportion and number of T regulatory cells Cell Mol Immunol 7 2010 157 162
    • (2010) Cell Mol Immunol , vol.7 , pp. 157-162
    • Liu, R.1    Xiong, S.2    Zhang, L.3    Chu, Y.4
  • 50
    • 0035328683 scopus 로고    scopus 로고
    • Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice
    • J.P. Machiels, R.T. Reilly, L.A. Emens Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res 61 2001 3689 3697 (Pubitemid 32694981)
    • (2001) Cancer Research , vol.61 , Issue.9 , pp. 3689-3697
    • Machiels, J.-P.H.1    Todd Reilly, R.2    Emens, L.A.3    Ercolini, A.M.4    Lei, R.Y.5    Weintraub, D.6    Okoye, F.I.7    Jaffee, E.M.8
  • 51
    • 79551514818 scopus 로고    scopus 로고
    • Cyclophosphamide induces differentiation of Th17 cells in cancer patients
    • S. Viaud, C. Flament, M. Zoubir Cyclophosphamide induces differentiation of Th17 cells in cancer patients Cancer Res 71 2011 661 665
    • (2011) Cancer Res , vol.71 , pp. 661-665
    • Viaud, S.1    Flament, C.2    Zoubir, M.3
  • 52
    • 40949157885 scopus 로고    scopus 로고
    • Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation
    • DOI 10.1158/1078-0432.CCR-07-0371
    • D. Laheru, E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation Clin Cancer Res 14 2008 1455 1463 (Pubitemid 351413929)
    • (2008) Clinical Cancer Research , vol.14 , Issue.5 , pp. 1455-1463
    • Laheru, D.1    Lutz, E.2    Burke, J.3    Biedrzycki, B.4    Solt, S.5    Onners, B.6    Tartakovsky, I.7    Nemunaitis, J.8    Le, D.9    Sugar, E.10    Hege, K.11    Jaffee, E.12
  • 53
    • 29444433283 scopus 로고    scopus 로고
    • Combining cancer vaccines with chemotherapy
    • DOI 10.1517/14656566.6.16.2813
    • G. Chong, M.A. Morse Combining cancer vaccines with chemotherapy Expert Opin Pharmacother 6 2005 2813 2820 (Pubitemid 43009544)
    • (2005) Expert Opinion on Pharmacotherapy , vol.6 , Issue.16 , pp. 2813-2820
    • Chong, G.1    Morse, M.A.2
  • 54
    • 77951086882 scopus 로고    scopus 로고
    • 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity
    • J. Vincent, G. Mignot, F. Chalmin 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res 70 2010 3052 3061
    • (2010) Cancer Res , vol.70 , pp. 3052-3061
    • Vincent, J.1    Mignot, G.2    Chalmin, F.3
  • 55
    • 78349313304 scopus 로고    scopus 로고
    • Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model
    • H.S. Kim, H.M. Park, J.S. Park Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model Vaccine 28 2010 7787 7796
    • (2010) Vaccine , vol.28 , pp. 7787-7796
    • Kim, H.S.1    Park, H.M.2    Park, J.S.3
  • 56
    • 77956680680 scopus 로고    scopus 로고
    • A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers
    • K.N. Kodumudi, K. Woan, D.L. Gilvary, E. Sahakian, S. Wei, J.Y. Djeu A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers Clin Cancer Res 16 2010 4583 4594
    • (2010) Clin Cancer Res , vol.16 , pp. 4583-4594
    • Kodumudi, K.N.1    Woan, K.2    Gilvary, D.L.3    Sahakian, E.4    Wei, S.5    Djeu, J.Y.6
  • 57
    • 77952549994 scopus 로고    scopus 로고
    • Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
    • L.W. Pfannenstiel, S.S. Lam, L.A. Emens, E.M. Jaffee, T.D. Armstrong Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice Cell Immunol 263 2010 79 87
    • (2010) Cell Immunol , vol.263 , pp. 79-87
    • Pfannenstiel, L.W.1    Lam, S.S.2    Emens, L.A.3    Jaffee, E.M.4    Armstrong, T.D.5
  • 58
    • 33745612716 scopus 로고    scopus 로고
    • The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration
    • DOI 10.1007/s00262-005-0116-4
    • R.A. Prell, L. Gearin, A. Simmons, M. Vanroey, K. Jooss The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration Cancer Immunol Immunother 55 2006 1285 1293 (Pubitemid 43992054)
    • (2006) Cancer Immunology, Immunotherapy , vol.55 , Issue.10 , pp. 1285-1293
    • Prell, R.A.1    Gearin, L.2    Simmons, A.3    VanRoey, M.4    Jooss, K.5
  • 59
    • 73349084990 scopus 로고    scopus 로고
    • Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation
    • L.A. Emens, J.M. Asquith, J.M. Leatherman Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation J Clin Oncol 27 2009 5911 5918
    • (2009) J Clin Oncol , vol.27 , pp. 5911-5918
    • Emens, L.A.1    Asquith, J.M.2    Leatherman, J.M.3
  • 60
    • 33745860066 scopus 로고    scopus 로고
    • CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism
    • J.J. Engelhardt, T.J. Sullivan, J.P. Allison CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism J Immunol 177 2006 1052 1061 (Pubitemid 44036607)
    • (2006) Journal of Immunology , vol.177 , Issue.2 , pp. 1052-1061
    • Engelhardt, J.J.1    Sullivan, T.J.2    Allison, J.P.3
  • 62
    • 0033517152 scopus 로고    scopus 로고
    • Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony- stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
    • DOI 10.1084/jem.190.3.355
    • A. van Elsas, A.A. Hurwitz, J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 1999 355 366 (Pubitemid 29374833)
    • (1999) Journal of Experimental Medicine , vol.190 , Issue.3 , pp. 355-366
    • Van Elsas, A.1    Hurwitz, A.A.2    Allison, J.P.3
  • 63
    • 33745851479 scopus 로고    scopus 로고
    • CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    • DOI 10.1172/JCI27745
    • S.A. Quezada, K.S. Peggs, M.A. Curran, J.P. Allison CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells J Clin Invest 116 2006 1935 1945 (Pubitemid 44033317)
    • (2006) Journal of Clinical Investigation , vol.116 , Issue.7 , pp. 1935-1945
    • Quezada, S.A.1    Peggs, K.S.2    Curran, M.A.3    Allison, J.P.4
  • 64
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • F.S. Hodi, S.J. O'Day, D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 66
    • 77954899030 scopus 로고    scopus 로고
    • Phase i study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
    • J.R. Brahmer, C.G. Drake, I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
    • (2010) J Clin Oncol , vol.28 , pp. 3167-3175
    • Brahmer, J.R.1    Drake, C.G.2    Wollner, I.3
  • 67
    • 63449124514 scopus 로고    scopus 로고
    • Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors
    • B. Li, M. VanRoey, C. Wang, T.H. Chen, A. Korman, K. Jooss Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors Clin Cancer Res 15 2009 1623 1634
    • (2009) Clin Cancer Res , vol.15 , pp. 1623-1634
    • Li, B.1    Vanroey, M.2    Wang, C.3    Chen, T.H.4    Korman, A.5    Jooss, K.6
  • 68
    • 79956103042 scopus 로고    scopus 로고
    • Anti-TIM3 antibody promotes T cell IFN-{gamma}-mediated anti-tumor immunity and suppresses established tumors
    • S.F. Ngiow, B. von Scheidt, H. Akiba, H. Yagita, M.W. Teng, M.J. Smyth Anti-TIM3 antibody promotes T cell IFN-{gamma}-mediated anti-tumor immunity and suppresses established tumors Cancer Res 71 2011 3540 3551
    • (2011) Cancer Res , vol.71 , pp. 3540-3551
    • Ngiow, S.F.1    Von Scheidt, B.2    Akiba, H.3    Yagita, H.4    Teng, M.W.5    Smyth, M.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.